Impact of Biodecoding on disability associated with migraine
DOI:
https://doi.org/10.62486/agmu202537Keywords:
impact of headache, migraine disability, biodecodingAbstract
Introduction: migraine is a common neurological disease. 53% of patients have severe disability.Biodecoding is a holistic method that allows us to know through symptoms what the emotional origin of an illness may be.
Methods: an experimental research was designed, pretest-postest and with a control group .40 patients were included in the study,20 who received treatment only with gabapentin (control group) and 20 who were additionally treated with biodecoding (study group). The response was evaluated one month and three months after the intervention. Descriptive statistics and inferences were used to analyze the data.
Results: before the intervention, 75% of the patients in both groups had a very severe headache impact. One month after treatment, 70% of the patients in the study group had 15% in the control group had little or no impact. By the third month, 95% of the patients in the study group and 65% of the patients in the control group had little or no impact of the headache. Before treatment, 100% of the patients presented severe disability, after three months this disability had a statistically significant improvement.
Conclusions: biodecoding reduces the severe impact of headache and reduces migraine disability
References
Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care. [Internet]. 2019. [Consultado julio 2023]; 25(2 Suppl):23-34. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30681821/.
Garzón Cutiño L, Valdés Izquierdo LE, Valdés Santiago D, Coello Caballero H. Clinical characterization of women with migraine in neurology consultation. AG Salud. 2024; 2:99. https://doi.org/10.62486/agsalud202499. DOI: https://doi.org/10.62486/agsalud202499
Santos-Lasaosa S, Belvis R, Cuadrado ML, Díaz-Insa S, Gago-Veiga AB, Guerrero-Peral AL, Huerta M, Irimia P, Láinez JM, Latorre G, Leira R, Pascual J, Porta-Etessam J, Sánchez del Río M, Viguera J, Pozo-Rosich P. CGRP en migraña: de la fisiopatología a la terapéutica. Neurología. [Internet]. 2022. [Consultado Marzo 2024]; 37(5). Disponible en: https://doi.org/10.1016/j.nrl.2019.03.013. DOI: https://doi.org/10.1016/j.nrl.2019.03.013
Solano-Mora A, Ramírez-Vargas X, Solano-Castillo A. Actualización de la Migraña. Revista Médica Sinergia. [Internet]. 2020. [Consultado Marzo 2024]; 5(4):e447. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=7398772 DOI: https://doi.org/10.31434/rms.v5i4.447
Valdés-Izquierdo LE, Herrera-Wainshtok AC, Varela-Rodríguez LA, Solernou-Mesa IA. AELI® KINETEST, complemento para el diagnóstico clínico. Educación Médica Superior. [Internet]. 2023. [Consultado Diciembre 2023]; 37(2):e3852. https://ems.sld.cu/index.php/ems/article/view/3852. DOI: https://doi.org/10.56294/saludcyt202258
Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the Headache Impact Test (HIT-6TM) across episodic and chronic migraine. Cephalalgia. [Internet]. 2011. [Consultado Marzo 2024]; 31(3):357-67. Disponible en: https://pubmed.ncbi.nlm.nih.gov/20819842/. DOI: https://doi.org/10.1177/0333102410379890
Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. [Internet]. 2000. [Consultado Marzo 2024]; 88(1):41–52. Disponible en: https://pubmed.ncbi.nlm.nih.gov/11098098/. DOI: https://doi.org/10.1016/S0304-3959(00)00305-5
Barrientos UN, Juliet PR, Rapoport A, Salles GP, Milán SA, Meza CP. Cefalea por abuso de medicamentos y sus marcadores clínicos. Revista Chilena de Neuropsiquiatría. [Internet]. 2022. [Consultado Abril 2024]; 60(1):26-39. Disponible en: https://pesquisa.bvsalud.org/portal/resourcept/biblio-1388418. DOI: https://doi.org/10.4067/s0717-92272022000100026
McAllister P, Winner P, Chakhava G, Ailani J, Cady R, Ettrup A et al. Eptinezumab treatment initiated during a migraine attack prolonged the time to next migraine and improved HIT-6 outcomes. European Journal of Neurology. [Internet]. 2021. [Consultado Mayo 2024]; 28(227). Disponible en: http://dx.doi.org/10.1111/ene.14974. DOI: https://doi.org/10.1212/WNL.96.15_supplement.1622
Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen C, Josiassen M et al. Efficacy and safety of Eptinezumab for migraine prevention in patients with 2-4 prior preventive treatment failures. European Journal of Neurology. [Internet]. 2022. [Consultado Mayo 2024]; 29(418). Disponible en: http://dx.doi.org/10.1111/ene.15466. DOI: https://doi.org/10.1111/ene.15466
Augello S, Trujillo Y, Arjona M, Maderos I, Zayas B, Zarzabal Y. Acupuntura con estimulación manual en la cefalea migrañosa. Correo Científico Médico. [Internet]. 2015. [Consultado Mayo 2024]; 19:645-55. Disponible en: https://revcocmed.sld.cu/index.php/cocmed/article/view/2149/737.
Vázquez Guevara DD. Eficacia de memantina comparada con valproato de sodio en el tratamiento profiláctico de migraña. [Tesis de posgrado]. San Luis Potosí: Universidad Autónoma de San Luis Potosí; 2020. [Consultado Mayo 2024]. Disponible en: https://www.biblioiconografiamexicana.uaslp.mx/xmlui/handle/i /7724.
Barbanti P, Egeo G, Aurilia C, Torelli P, Finocchi C, d’Onofrio F et al. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study. Journal of Headache and Pain. [Internet]. 2023. [Consultado Mayo 2024]; 24(1):30. Disponible en: https://pubmed.ncbi.nlm.nih.gov/36949388/ DOI: https://doi.org/10.1186/s10194-023-01561-w
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Lisbel Garzón Cutiño, Libertad Engracia Valdés Izquierdo, Damian Valdés Santiago (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
